Free Trial
NASDAQ:AIKI

AIkido Pharma (AIKI) Stock Price, News & Analysis

AIkido Pharma logo
$5.66 +0.56 (+10.98%)
As of 05/2/2025

About AIkido Pharma Stock (NASDAQ:AIKI)

Key Stats

Today's Range
$5.00
$5.72
50-Day Range
$3.37
$8.32
52-Week Range
$3.31
$11.48
Volume
479,696 shs
Average Volume
79,326 shs
Market Capitalization
$31.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Receive AIKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.

AIKI Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Dominari Holdings Inc trading resumes
SNOA Sonoma Pharmaceuticals, Inc.
Royalty Pharma PLC
See More Headlines

AIKI Stock Analysis - Frequently Asked Questions

AIkido Pharma's stock was trading at $0.9844 at the beginning of the year. Since then, AIKI shares have increased by 475.0% and is now trading at $5.66.
View the best growth stocks for 2025 here
.

Shares of AIkido Pharma reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

The following companies are subsidiaries of AIkido Pharma: Hoth Therapeutics.

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Therapeutics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and

Company Calendar

Today
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:AIKI
Employees
4
Year Founded
1967

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Price / Cash Flow
N/A
Book Value
$19.27 per share
Price / Book
0.29

Miscellaneous

Free Float
5,013,000
Market Cap
$31.05 million
Optionable
Not Optionable
Beta
0.93

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:AIKI) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners